Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Drops By 28.2%

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 35,200 shares, a drop of 28.2% from the March 31st total of 49,000 shares. Approximately 1.9% of the shares of the stock are short sold. Based on an average daily volume of 339,800 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Several research analysts have commented on TENX shares. Roth Mkm reissued a “buy” rating on shares of Tenax Therapeutics in a report on Tuesday, February 20th. StockNews.com started coverage on shares of Tenax Therapeutics in a report on Wednesday, January 10th. They issued a “sell” rating for the company.

Tenax Therapeutics Stock Performance

Tenax Therapeutics stock traded down $0.12 during mid-day trading on Friday, hitting $3.48. The company’s stock had a trading volume of 16,887 shares, compared to its average volume of 31,019. The business has a 50 day moving average price of $3.94 and a 200-day moving average price of $13.98. Tenax Therapeutics has a 12 month low of $3.47 and a 12 month high of $61.20.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.